**1) Sponsor(s):**National Institutes of Health (NIH)

**Program Title:** [Notice of Special Interest (NOSI): Repurposing Existing Therapeutics to Address the 2019 Novel Coronavirus Disease (COVID-19)](https://grants.nih.gov/grants/guide/notice-files/NOT-TR-20-012.html)

**Deadline:** Between June 5, 2020 and October 16, 2020

**Description of Opportunity:** National Center for Advancing Translational Sciences (NCATS) is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on the 2019 novel coronavirus (SARS-CoV-2) and the disease it causes, i.e., “coronavirus disease 2019” (COVID-19). NCATS is particularly interested in projects that repurpose existing drugs or biologics (existing therapeutics) that have already begun or completed a Phase I clinical trial.

The hypothesis for proposed studies must be developed using innovative processes to identify the therapeutic/indication pair. Examples include the following:

Testing a publicly posted therapeutic candidate for use to treat COVID-19. Examples include clinical candidate therapeutics in documents publicly posted by the World Health Organization (types/classes of candidate therapeutics) and (candidates for clinical evaluation).

Testing a candidate therapy to treat COVID-19 that was already identified with a publicly available computational approach.

Testing of existing therapeutic candidates that work on mechanistic targets shared among other viruses that may be relevant to SARS-CoV-2.

NCATS is soliciting applications to PAR-17-465, PAR-18-462, and PAR-18-332.

**2) Sponsor(s):**Department of Housing and Community Development

**Program: Title:** [Homekey](https://www.grants.ca.gov/grants/homekey-2/)

**Deadline:** September 29, 2020

**Description of Opportunity:** Homekey provides funding to rapidly sustain and expand the inventory of housing for people experiencing homelessness or at risk of homelessness and impacted by COVID-19. Homekey is an opportunity for local public agencies to purchase motels and a broad range of other housing types in order to increase their community's capacity to respond to homelessness and the current COVID-19 pandemic.

The Department requires all Applicants to engage in a pre-application consultation with the Department and/or the Department of General Services (DGS) prior to submitting an application. Application consultations will be available upon the release of this NOFA and may be requested by emailing [Homekey@hcd.ca.gov](mailto:Homekey@hcd.ca.gov).

The list of eligible uses for the CRF $550 million allocation and the $50 million state General Fund allocation is as follows: i. Acquisition or rehabilitation of motels, hotels, or hostels. ii. Master leasing of properties.iii. Acquisition of other sites and assets, including purchase of apartments or homes, adult residential facilities, residential care facilities for the elderly, manufactured housing, and other buildings with existing residential uses that could be converted to permanent or interim housing. iv. Conversion of units from nonresidential to residential in a structure with a certificate of occupancy as a motel, hotel, or hostel. v. The purchase of affordability covenants and restrictions for units.vi. Relocation costs for individuals who are being displaced as a result of rehabilitation of existing units. vii. Capitalized operating subsidies for units purchased, converted, or altered with funds provided pursuant to Health and Safety Code section 50675.1.1.\*

\*Projects seeking capitalized operating subsidies for units purchased, converted, or altered will be awarded with funds from the $50 million state General Fund allocation. The $550 million in Homekey derived from the CRF is not permitted to be used for this purpose.

**3) Sponsor(s):**Department of Education

**Program: Title:** [Higher Education Emergency Relief Fund – IHEs](https://www2.ed.gov/about/offices/list/ope/caresact.html)

**Deadline:** September 30, 2020

**Description of Opportunity:** The CARES Act provides institutions with significant discretion on how to award this emergency assistance to students. This means that each institution may develop its own system and process for determining how to allocate these funds, which may include distributing the funds to all students or only to students who demonstrate significant need. The only statutory requirement is that the funds be used to cover expenses related to the disruption of campus operations due to coronavirus (including eligible expenses under a student’s cost of attendance, such as food, housing, course materials, technology, health care, and child care). With that said, I would like to encourage the leadership of each institution to prioritize your students with the greatest need, but at the same time consider establishing a maximum funding threshold for each student to ensure that these funds are distributed as widely as possible. As a point of reference, you might consider using the maximum Federal Pell grant (for the 2019-2020 academic year, $6,195) as that threshold.

In order to access these funds, all institutions must sign and return the Certificate of Funding and Agreement via: grants.gov (<https://www.grants.gov/web/grants/applicants/registration.html>), acknowledging the terms and conditions of the funding. After the Department has received the certificate, institutions may draw down their emergency assistance funds using the Department’s

G5 system.

**4) Sponsor(s):**Department of Defense – Department of the Air Force

**Program: Title:** [Commercial Solution Opening - CSO\_COVID\_19 Response](https://beta.sam.gov/opp/f48d23af514f494f819f0c33e9f40e17/view)

**Deadline:** September 30, 2020

**Description of Opportunity:** The Department of the Air Force (DAF) has been tasked to address mission needs in response to the national crisis caused by the COVID-19 pandemic. The Air Force Senior Acquisition Executive (SAE) established the Department of the Air Force Acquisition COVID-19 Task Force (DAF ACT) across the acquisition enterprise (i) to execute all requirements from the Office of the Under Secretary of Defense for Acquisition and Sustainment Joint Acquisition Task Force, (JATF) and (ii) to collect and consolidate funding requests needed to recover programs from COVID-19 impacts. The DAF ACT contains four primary lines of effort (LOE’s): (1) Relief for external assistance requirements; (2) Resilience for Defense Industrial Base Efforts; (3) Recovery for consolidating funding requests that minimize program impacts; and (4) Rapid for solicitation and execution of large-scale rapid small business contracts across all lines of effort.

MISSION FOCUS AREAS

I. Combating the Spread (predictive analytics, next hotspot, threat to current activities, decision support, etc.)

II. Welfare of Citizens (effects to transportation, movement of people and goods, education and development, physical training, regular HR functions, job transition, etc.)

III. Readiness (continuing operations through the outbreak, coordinating with allies and partners, continuing long term projects, etc.)

IV. Logistics (security and protection, supply chain protection and assessment, etc.)

V. Industrial Base Impacts (impacts on small businesses, payments, contracts, large system programs, protection and expansion of critical assets, etc.)

VI. Medical (telehealth, medical capacity and sustainment, medical supplies and equipment, etc.)

VII. Other - Any solution/proposal that is not covered by the above topic areas but support the national response to the COVID-19 pandemic

**5) Sponsor(s):**Engineering and Physical Sciences Research Council

**Program: Title:** [Medical robotics for contagious diseases challenge](https://www.ukras.org/robotics-week/challenges/medical-robotics-for-contagious-diseases-challenge-2020/)

**Deadline:** September 30, 2020

**Description of Opportunity:** The Engineering and Physical Sciences Research Council, through the UK-RAS Network and in collaboration with Imperial College London, Wellcome, KUKA and Intuitive Surgical, invites submissions for its medical robotics for contagious diseases challenge. This seeks innovative ideas that could aid in the response to the current COVID-19 pandemic and future global pandemics. The COVID-19 pandemic offers a unique opportunity to galvanise medical robot technologies, as they play an increasingly major role in combating contagious diseases.

**6) Sponsor(s):**National Institutes of Health (NIH)

**Program: Title:** [NIH Directors Emergency Transformative Research Awards (R01 Clinical Trial Optional)](https://grants.nih.gov/grants/guide/rfa-files/RFA-RM-20-020.html)

**Deadline:** September 30, 2020

**Description of Opportunity:** This FOA solicits applications responsive only to the COVID-19 public health emergency through support of the CARES Act. All other Transformative Research Award applications must be submitted in response to RFA-RM-20-013.

**7) Sponsor(s):**Department of Homeland Security (DHS)

**Program: Title:** [Emerging Needs: COVID-19 Response and Future Mitigation](https://beta.sam.gov/opp/01cbeafa8c0e47428ddd30693b4c47d6/view?keywords=%22Emerging%20Needs%22&sort=-relevance&index=&is_active=true&page=1&date_filter_index=0&inactive_filter_values=false&organization_id=100013095&refresh=y)

**Deadline:** September 30, 2020

**Description of Opportunity:** This Other Transaction Solicitation (OTS) Call (70RSAT20R00000044) – COVID-19 Response & Future Mitigation is a technical call issued against Department of Homeland Security (DHS), Science & Technology (S&T), Silicon Valley Innovation Program (SVIP), 5-Year Innovation Other Transaction Solicitation (OTS), HSHQDC-16-R-B0005 (current issue).  The OTS describes the overarching program details whereas the call describes the specific problem set.

The COVID-19 pandemic has had an impact on many facets of DHS operations as well as the health and safety of agents, officers and the public.  While this SVIP COVID-19 Response & Future Mitigation Topic Call is intended to address several near-term use cases in response to the current pandemic, it is envisioned these solutions will have broader application to enhancing DHS operations as well as prepare DHS for any future mitigation.

As DHS, state and local agencies, private industry and the public respond to the impacts of the COVID-19 pandemic and eventually resume operations safely within the context of a COVID-19 environment, there exists the need for solutions for a variety of purposes across DHS as well as our state and local and other Federal partners. The following illustrative scenarios / use cases are intended to describe where the technologies being sought by DHS in this topic call could potentially be applied: (1) Test and Validation Service for Security & Privacy of Contact Tracing Apps (2) Video Analytics for Self-Screening at TSA Checkpoints (3) Methods to Rapidly Disinfect Surfaces at TSA Checkpoints and other DHS Facilities (4) Collection and Integration of Authoritative Quantitative Open-Source Information (5) Stand-Off Methods for Point of Care Entry Detection at DHS Facilities

**8) Sponsor(s):**National Institutes of Health (NIH)

**Program Title:** [Notice of Special Interest (NOSI): Availability of Administrative Supplements and Revision Supplements on Coronavirus Disease 2019 (COVID-19)](https://grants.nih.gov/grants/guide/notice-files/NOT-HL-20-757.html)

**Deadline:** October 5, 2020

**Description of Opportunity:** NHLBI is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on Coronavirus Disease 2019 (COVID-19) and on biological effects of its causative agent, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Topics of specific interest to NHLBI include host response, associations with heart, lung, and blood (HLB) diseases, potential impacts on transfusion safety, and clinical outcomes of infected individuals.

**9) Sponsor(s):**National Institutes of Health (NIH)

**Program Title:** [Notice of Special Interest (NOSI): Availability of Administrative Supplements and Revision Supplements on Coronavirus Disease 2019 (COVID-19)](https://grants.nih.gov/grants/guide/notice-files/NOT-HL-20-757.html)

**Deadline:** October 5, 2020

**Description of Opportunity:** To better understand the host response, associated HLB disease, impact on transfusion safety, and short- and long-term clinical outcomes of individuals infected with SARS-CoV-2, the NHLBI encourages the submission of applications for Administrative Supplements and Competitive Revisions to active NHLBI grants to support research on SARS-CoV-2 and HLB COVID-19 disease. Of particular interest are studies that take advantage of human research or unique model systems to study the consequences of SARS-CoV-2 infection. Supported research is expected to inform future efforts to diagnose, prevent, mitigate, or treat this viral infection and associated HLB manifestations.

**10) Sponsor(s):**National Institutes of Health (NIH)

**Program Title:** [Notice of special interest – emergency competitive revisions on coronavirus disease 2019 for currently active NHLBI phase I-III clinical trials](https://grants.nih.gov/grants/guide/notice-files/NOT-HL-20-782.html)

**Deadline:** October 5, 2020

**Description of Opportunity:** This supports research focusing on the safety and efficacy of interventions for primary prevention or treatment of COVID-19, associated clinical phenotypes and surrogate outcomes relevant to heart, lung and blood diseases. The maximum project period is two years.

**11) Sponsor(s):**National Institutes of Health (NIH)

**Program Title:** [Notice of Special Interest (NOSI): Availability of Administrative Supplements and Urgent Competitive Revisions for Research on Stress Management in Relation to Coronavirus Disease 2019 (COVID-19)](https://grants.nih.gov/grants/guide/notice-files/NOT-AT-20-011.html)

**Deadline:** October 6, 2020

**Description of Opportunity:** NCCIH is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on the 2019 Novel Coronavirus (2019-nCoV, also known as COVID-19). Topics of specific interest for this NOSI include research on stress management strategies, including mind and body approaches, that individuals may engage in remotely to address stressors related to social distancing, as well as to address recovery and recurrence of symptoms during and after COVID-19 infections.

**12) Sponsor(s):**National Institutes of Health (NIH)

**Program Title:** [Laboratory, Data Analysis, and Coordinating Center (LDACC) for the Developmental Genotype-Tissue Expression Project (U24 Clinical Trial Not Allowed)](https://grants.nih.gov/grants/guide/rfa-files/RFA-HG-20-039.html)

**Deadline:** October 13, 2020 (LOI)

**Description of Opportunity:** The National Human Genome Research Institute (NHGRI) and the Eunice Kennedy Shriver National Institute of Child Health and Human Development are coordinating efforts for establishing a Developmental Genotype-Tissue Expression (dGTEx) Project, to catalog and analyze transcriptional profiles from a wide variety of tissues obtained from neonates, children, and adolescents in a post-mortem setting. The purpose of this FOA is to solicit applications to develop and implement a Laboratory, Data Analysis, and Coordinating Center (LDACC) for the Developmental Genotype-Tissue Expression (dGTEx) Project. The LDACC will perform 2 major functions: a molecular laboratory, and a data analysis and coordinating center. As a molecular laboratory, the LDACC will work with the Biospecimen Procurement Center (BPC) funded by NICHD to process tissue samples for sequencing and biobanking. Responsibilities as a data analysis and coordinating center include ensuring close coordination with the BPC, monitoring study progress and laboratory performance, performing basic analysis of data for gene expression analyses, and harmonizing and submitting datasets to be deposited in repositories such as the AnVIL (Analysis, Visualization, and Informatics Lab-space).

**13) Sponsor(s):**National Institutes of Health (NIH)

**Program Title:** [Notice of Special Interest (NOSI): Repurposing Existing Therapeutics to Address the 2019 Novel Coronavirus Disease (COVID-19)](https://grants.nih.gov/grants/guide/notice-files/NOT-TR-20-012.html)

**Deadline:** October 16, 2020

**Description of Opportunity:** National Center for Advancing Translational Sciences (NCATS) is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on the 2019 novel coronavirus (SARS-CoV-2) and the disease it causes, i.e., “coronavirus disease 2019” (COVID-19). NCATS is particularly interested in projects that repurpose existing drugs or biologics (existing therapeutics) that have already begun or completed a Phase I clinical trial.

**14) Sponsor(s):**National Institutes of Health (NIH)

**Program Title:** [National Institute for Occupational Safety and Health - NIOSH Centers of Excellence for Total Worker Health® (U19)](https://grants.nih.gov/grants/guide/pa-files/PAR-20-297.html)

**Deadline:** November 2, 2020 (letter of intent)

**Description of Opportunity:** NIOSH/CDC invites applications for the NIOSH Centers of Excellence for Total Worker Health (TWH). The purpose of this FOA is to solicit meritorious applications for Centers of Excellence for TWH to develop and conduct a broad range of multidisciplinary research, intervention, outreach and education, and evaluation activities that advance the overall safety, health, and well-being of the diverse population of workers in our nation. Center structure should take advantage of diverse scientific resources and focus on local, regional, or national worker safety and health issues. Centers should emphasize creating and implementing evidence-based solutions to address evolving challenges and opportunities related to worker safety, mental and physical health, and well-being. Collaborations in partnership with academic institutions, nonprofit organizations, and other groups focused on occupational safety and health are expected. Applicants must concisely describe the occupational health burden within their service area and directly link research and outreach activities to help alleviate the burden. Applicants should also clearly articulate the anticipated impacts of the proposed work, both during the project period and beyond.

Today’s workers face not only the traditional risks of chemical, physical, and biological hazards but also increased risks related to the changing nature of work, shifting workforce demographics and diversity, and evolving employment patterns. The changing workplace environment also contributes to stress, mental health effects, chronic diseases and other impacts on population health and well-being.

At the time of publishing this FOA, the COVID-19 pandemic has changed the workplace environment and increased worker concerns about economic insecurity, mental health and well-being, isolation and other challenges of working remotely, and reintegrating back into the workplace safely. New and daily challenges in the workplace, families, and communities create emerging conditions that increase allostatic loading (the wear and tear of ongoing stress experienced by individuals) and may affect cognitive reserve and resilience, and potentially lead to cognitive decline. Gender, age and socioeconomic characteristics of workers may affect their sensitivity to these emerging conditions.

The National Institute for Occupational Safety and Health’s (NIOSH) TWH Program builds on four decades of scientific knowledge through the recognition that work is a social determinant of health; job-related factors such as wages, hours of work, workload and stress levels, interactions with coworkers and supervisors, access to paid leave, and health-promoting workplaces all can have an important impact on the well-being of workers, their families, and their communities. TWH is defined as policies, programs and practices that integrate protection from work-related safety and health hazards with promotion of injury and illness prevention efforts to advance worker well-being. This approach prioritizes a hazard-free work environment for all workers and comprehensively integrates workplace systems relevant to the control of hazards and exposures, organization of work, compensation and benefits, work-life integration/management, and organizational change management. The NIOSH TWH program supports ground-breaking research and practical applications that address the implications of today’s changing workplace and responds to demands for information and practical solutions to the health, safety, and well-being challenges that workers face.

**15) Sponsor(s):**National Institutes of Health (NIH)

**Program Title:** [Notice of Special Interest (NOSI): Availability of Emergency Competitive Revisions and Administrative Supplements to Clinical and Translational Science Award (CTSA) Program Awards to Address 2019 Novel Coronavirus Disease (COVID-19) Public Health Needs](https://grants.nih.gov/grants/guide/notice-files/NOT-TR-20-028.html)

**Deadline:** November 10, 2020

**Description of Opportunity:** Purpose: The National Center for Advancing Translational Sciences (NCATS) is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for projects that address the COVID-19 Public Health Emergency. The Clinical and Translational Science Award (CTSA) Program is uniquely qualified to contribute to these efforts. NCATS is soliciting applications for Administrative Supplements (through PA-18-591) and Emergency Competitive Revisions (through PA-20-135) from current Clinical and Translational Science Award (CTSA) UL1 and U24 award recipients.

**16) Sponsor(s):**Environmental Protection Agency

**Program Title:** [Center for Early Lifestage Vulnerabilities to Environmental Stressors](https://www.grants.gov/web/grants/view-opportunity.html?oppId=328838)

**Deadline:** November 12, 2020

**Description of Opportunity:** The U.S. Environmental Protection Agency (EPA), as part of its Science to Achieve Results (STAR) program, is seeking applications to support a Center for Early Lifestage Vulnerabilities to Environmental Stressors. EPA is interested in supporting a transdisciplinary research center to better understand potential causal relationships among cumulative exposures to chemicals and non-chemical environmental stressors during early lifestages and modifying factors that result in adverse developmental health effects. Developmental health outcomes may include attention deficit/hyperactivity disorder (ADHD), reduced IQ, obesity, lessened self-regulatory capacities, anxiety, depression, attention problems, lower memory function, or structural changes to the brain. The application should include the development and demonstration of novel and revolutionary quantitative methods and approaches to integrate multidisciplinary data (epidemiology, toxicology, exposure science, risk assessment, public health, social science, and environmental science).

**17) Sponsor(s):**National Institutes of Health (NIH)

**Program Title:** [Mechanistic Studies of the Interaction between SARS-CoV-2/COVID-19 and Diseases and Organ Systems of Interest to NIDDK (R01 Clinical Trial Optional)](https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-20-021.html)

**Deadline:** November 16, 2020 (Letter of Intent)

**Description of Opportunity:** The purpose of this Funding Opportunity Announcement (FOA) is to support basic and clinical mechanistic research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) susceptibility, routes of infection, course of disease, morbidity and mortality in people with pre-existing diseases, or adverse acute or chronic outcomes in organs, tissues, and biological systems of specific interest to NIDDK. These include diabetes and other metabolic diseases, obesity, and endocrine, digestive, liver, pancreas, kidney, urological, and hematologic tissues and diseases.

**18) Sponsor(s):**National Institutes of Health (NIH)

**Program Title:** [Notice of Special Interest (NOSI): Digital Healthcare Interventions to Address the Secondary Health Effects Related to Social, Behavioral, and Economic Impact of COVID-19](https://grants.nih.gov/grants/guide/notice-files/NOT-MH-20-053.html)

**Deadline:** Applications will be accepted on a rolling basis from June 10, 2020 through December 15, 2020

**Description of Opportunity:** This Notice of Special Interest (NOSI) highlights interest in research to strengthen the healthcare response to Coronavirus Disease 2019 (COVID-19) caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and to future public health emergencies, including pandemics. While the direct clinical effects of COVID-19 are supported by other funding opportunities, the purpose of this NOSI is to support research to address secondary health effects of the social, behavioral, and economic changes, particularly among populations who experience [health disparities](https://www.nimhd.nih.gov/about/overview/)and vulnerable populations through the use of digital health assessments and interventions to yield measurable near-term impact.

**19) Sponsor(s):**National Institutes of Health (NIH)

**Program Title:** [Notice of Special Interest (NOSI): Competitive and Administrative Supplements for Community Interventions to Reduce the Impact of COVID-19 on Health Disparity and Other Vulnerable Populations](https://grants.nih.gov/grants/guide/notice-files/NOT-MD-20-022.html)

**Deadline:** Applications will be accepted on a rolling basis from June 10, 2020 through December 15, 2020

**Description of Opportunity:** The COVID-19 pandemic and its associated mitigation strategies are expected to have significant psychosocial, behavioral, and socioeconomic impacts on health, which are exacerbated in populations that experience health disparities and other vulnerable groups, leading to disproportionately adverse consequences. Those experiencing health disparities prior to the COVID-19 pandemic are at increased risk of infection and other COVID-19 related consequences (e.g., job loss, unpaid leave, lost wages).

Research is needed to test community interventions focused on the prevention (or slowing) of COVID-19 transmission, evaluate local and state policies and programs intended to mitigate COVID-19 exposure and improve adherence, and reduce the negative impact of the multifaceted consequences on the health of populations who experience health disparities and other vulnerable groups. This work may include leveraging and scaling existing resources (e.g., health education materials, technology, social media, mass media, social support networks, social services). In domains and populations in which the evidence base is limited, the development, testing, and implementation of novel or adapted interventions to address the negative health consequences of the COVID-19 pandemic (including the unintended health consequences of population-level interventions) may also be needed to address the unique needs of populations.

**20) Sponsor(s):**National Institutes of Health (NIH)

**Program Title:** [Mechanistic Studies of the Interaction between SARS-CoV-2/COVID-19 and Diseases and Organ Systems of Interest to NIDDK (R01 Clinical Trial Optional)](https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-20-021.html)

**Deadline:** December 16, 2020

**Description of Opportunity:** The purpose of this Funding Opportunity Announcement (FOA) is to support basic and clinical mechanistic research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) susceptibility, routes of infection, course of disease, morbidity and mortality in people with pre-existing diseases, or adverse acute or chronic outcomes in organs, tissues, and biological systems of specific interest to NIDDK. These include diabetes and other metabolic diseases, obesity, and endocrine, digestive, liver, pancreas, kidney, urological, and hematologic tissues and diseases.

**21) Sponsor(s):**National Institutes of Health (NIH)

**Program Title:** [NIA Multi-site COVID-19 Related Clinical Trial Implementation Grant on Aging-Related Topics in at-risk Older Adult Populations (R01 Clinical Trial Required)](https://grants.nih.gov/grants/guide/pa-files/PAR-20-234.html?utm_source=dlvr.it&utm_medium=twitter)

**Deadline:** July 1, 2020; August 3, 2020; September 1, 2020; October 1, 2020; November 2, 2020; December 1, 2020; January 4, 2021; and February 1, 2021

**Description of Opportunity:** This Funding Opportunity Announcement (FOA) invites applications for implementation of investigator-initiated multi-site clinical trials (all phases or [stages](https://www.nia.nih.gov/research/dbsr/nih-stage-model-behavioral-intervention-development)) of interventions focused on specific aging-related issues to reducing transmission, risk, morbidity, mortality, severity, or complications of Coronavirus Disease 2019 (COVID-19). Applications on the following priority topics are invited:

* Efficacy and safety of interventions that target aging-related biological mechanisms that may influence risk or severity of COVID-19 infection among at-risk older adults
* Efficacy and safety of preventive and treatment interventions in older patients with differing comorbid conditions that make them especially vulnerable to adverse outcomes of COVID-19 infection
* Effectiveness of health and/or custodial care practices to reduce transmission risk or improve outcomes of COVID-19 infection in nursing homes or other residential settings serving at-risk older persons, including the development and testing of infection control training procedures for healthcare workers
* Rapid pragmatic trials in (at least two) health systems, nursing homes, or adult living facilities, ensuring replication across large pragmatic trial sites and leveraging electronic health records to promote quality improvement in physician, hospital, palliative care, and hospice practices to improve outcomes for older patients with COVID-19, especially those with cognitive impairment, Alzheimer's disease or Alzheimer's disease-related dementias (AD/ADRD), or underlying comorbidities
* Trials in at-risk older adults age 65 and older for whom electronic medical records are available and long-term outcomes can be tracked, and in institutions serving those populations
* Trials in older adults with AD/ADRD, older adults from populations with NIH-defined health disparities, and/or other vulnerable populations (e.g. incarcerated, homeless, living in institutions)

**22) Sponsor(s):**Department of Health and Human Services; Centers for Disease Control and Prevention

**Program Title:** [Annual Estimates of Influenza Vaccine Effectiveness for Preventing Medically Attended Laboratory-Confirmed Influenza in the United States](https://www.grants.gov/web/grants/view-opportunity.html?oppId=328584)

**Deadline:** January 8, 2021 (estimated)

**Description of Opportunity:** Influenza and other respiratory illnesses, including COVID-19, are important causes of morbidity, mortality, and healthcare burden across all age groups. For influenza vaccines, and for novel vaccines such as for COVID-19, estimates of vaccine effectiveness in preventing illness and associated complications are needed to evaluate the protection provided by nationwide vaccination programs. The goal of this notice of funding opportunity is to: a) support a network of US institutions that can obtain reliable vaccination information for a population, or cohort of individuals; b) provide accurate estimates of the effectiveness of vaccines against respiratory viruses including influenza, SARS-CoV-2 and other respiratory viruses that may emerge; and c) prevent medically attended influenza-associated illness in the population for whom influenza vaccination is recommended.

**23) Sponsor(s):**Department of Homeland Security – FEMA

**Program Title:** [FY20 Building Resilient Infrastructure and Communities](https://www.grants.gov/web/grants/view-opportunity.html?oppId=328472)

**Deadline:** January 21, 2021

**Description of Opportunity:** The Building Resilient Infrastructure and Communities (BRIC) program makes federal funds available to states, U.S territories, Indian tribal governments, and local communities for pre-disaster mitigation activities. The guiding principles of the program are to: (1) support state and local governments, tribes, and territories through capability- and capacity-building to enable them to identify mitigation actions and implement projects that reduce risks posed by natural hazards; (2) encourage and enable innovation while allowing flexibility, consistency, and effectiveness; (3) promote partnerships and enable high-impact investments to reduce risk from natural hazards with a focus on critical services and facilities, public infrastructure, public safety, public health, and communities; (4) provide a significant opportunity to reduce future losses and minimize impacts on the Disaster Relief Fund (DRF); and (5) support the adoption and enforcement of building codes, standards, and policies that will protect the health, safety, and general welfare of the public, take into account future conditions , and have long-lasting impacts on community risk-reduction, including for critical services and facilities and for future disaster costs.

In FY20 BRIC, FEMA will provide State/Territory allocations of $600,000 to states and territories and a Tribal Set-Aside of $20,000,000 for Indian tribal governments (federally-recognized) for mitigation projects and capability- and capacity-building (C&CB) activities. Any funds which are not awarded from the State/Territory Allocation or Tribal Set-Aside will be re-allocated to the national competition for mitigation projects.

**24) Sponsor(s):**National Institutes of Health (NIH)

**Program Title:** [Notice of Special Interest (NOSI) regarding the Availability of Urgent Competitive Revisions for Research on Coronavirus Disease 2019 (COVID-19) and the Causative Virus SARS-CoV-2](https://grants.nih.gov/grants/guide/notice-files/NOT-GM-20-025.html)

**Deadline:** February 5, 2021

**Description of Opportunity:** Coronaviruses are a diverse family of viruses that cause a range of disease in humans and animals, and there are currently no approved coronavirus vaccines or therapeutics. In January 2020, a novel coronavirus, SARS-CoV-2, was identified as the causative agent of an outbreak of viral pneumonia centered around Wuhan, Hubei Province, China. Current information regarding confirmed cases is changing daily and can be found on the Centers for Disease Control and Prevention website (https://www.cdc.gov/coronavirus/index.html) and through other sources. Transmission characteristics and the associated morbidity and mortality are not completely understood, but there is clear evidence of human-to-human transmission. Many other aspects of viral pathogenesis, natural history, and host range are poorly understood. Given this, there is an urgent public health need to better understand SARS-CoV-2, particularly to improve the predictive quality of existing models of spread, diagnostics for measurement of transmission, susceptibility and recovery, and development of therapeutic interventions.

NIGMS will accept the submission of applications for Competitive Revisions to active grants to address only the following research areas of interest:

* Incorporation of data related to SARS-CoV-2 into ongoing research efforts to develop predictive models for the spread of SARS-CoV-2 and other related infectious agents (all relevant grants).
* Repurposing or modification of diagnostic tools currently under development to enable rapid detection of SARS-CoV-2 infection (SBIR/STTR grants only).
* Rapid development of potential therapeutic agents for COVID-19 (SBIR/STTR only).

**25) Sponsor(s):**National Institutes of Health (NIH)

**Program Title:** [Notice of Special Interest (NOSI) regarding the Availability of Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus (2019-nCoV)](https://grants.nih.gov/grants/guide/notice-files/NOT-AI-20-030.html)

**Deadline:** February 6, 2021

**Description of Opportunity:** NIAID and NIGMS are issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on the 2019 novel Coronavirus (2019-nCoV). NIAID is particularly interested in projects focusing on viral natural history, pathogenicity, transmission, as well as projects developing medical countermeasures and suitable animal models for pre-clinical testing of vaccines and therapeutics against 2019-nCoV.

**26) Sponsor(s):**National Institutes of Health (NIH)

**Program Title:** [Digital Healthcare Interventions to Address the Secondary Health Effects Related to Social, Behavioral, and Economic Impact of COVID-19 (R01 - Clinical Trial Optional)](https://grants.nih.gov/grants/guide/pa-files/PAR-20-243.html)

**Deadline:** Applications due on August 20, 2020, December 2, 2020, and March 2, 2021

**Description of Opportunity:** This Funding Opportunity Announcement (FOA) aims to support research to strengthen the healthcare response to Coronavirus Disease 2019 (COVID-19) caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and future public health emergencies, including pandemics. While research related to the direct clinical effects of COVID-19 are supported by other funding opportunities, the purpose of this funding opportunity is to focus on the role and impact of digital health interventions [e.g., mobile health (mhealth), telemedicine and telehealth, health information technology (IT), and wearable devices] to address access, reach, delivery, effectiveness, scalability and sustainability of health assessments and interventions for secondary effects (e.g., behavioral health or self-management of chronic conditions) that are utilized during and following the pandemic, particularly in populations who experience health disparities and vulnerable populations.

**27) Sponsor(s):**National Institutes of Health (NIH)

**Program Title:** [Notice of Special Interest (NOSI) regarding the Availability of Emergency Competitive Revisions for Research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19)](https://grants.nih.gov/grants/guide/notice-files/NOT-AI-20-034.html)

**Deadline:** March 25, 2021

**Description of Opportunity:** This supports research on coronavirus disease with a particular focus on viral natural history, pathogenicity and transmission. The maximum project duration is two years.

**28) Sponsor(s):**National Institutes of Health (NIH)

**Program Title:** [Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements and Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus](https://grants.nih.gov/grants/guide/notice-files/NOT-DA-20-047.html)

**Deadline:** March 31, 2021

**Description of Opportunity:** NIDA is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on the 2019 Novel Coronavirus (2019-nCoV, also known as COVID-19). NIDA is especially interested in research collecting and examining data on the risks and outcomes for COVID-19 infection in individuals suffering from substance use disorders.

**29) Sponsor(s):**National Institutes of Health (NIH)

**Program Title:** [Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements and Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus and the Behavioral and Social Sciences](https://grants.nih.gov/grants/guide/notice-files/NOT-OD-20-097.html)

**Deadline:** March 31, 2021

**Description of Opportunity:** This Notice of Special Interest (NOSI) highlights the urgent need for social, behavioral, economic, health communication, and epidemiologic research relevant to the 2019 Novel Coronavirus (SARS-CoV-2) and COVID-19. This NOSI encourages urgent competitive supplements and administrative supplements to existing longitudinal studies that address key social and behavioral questions related to the COVID-19 pandemic, including adherence to and transmission mitigation from various containment and mitigation efforts; social, behavioral, and economic impacts from these containment and mitigation efforts; and downstream health impacts resulting from these social, behavioral, and economic impacts, including differences in risk and resiliency based on gender, race and ethnicity, socioeconomic status, and other social determinants of health.

**30) Sponsor(s):**National Institutes of Health (NIH)

**Program Title:** [Notice of Special Interest (NOSI): Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19)](https://grants.nih.gov/grants/guide/notice-files/NOT-AI-20-031.html)

**Deadline:** April 5, 2021

**Description of Opportunity:** NIAID is issuing this Notice of Special Interest (NOSI) to highlight the need for research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19). NIAID is particularly interested in projects focusing on viral natural history, pathogenicity, transmission, as well as projects developing medical countermeasures and suitable animal models for pre-clinical testing of vaccines and therapeutics against SARS-CoV-2/COVID-19.

**31) Sponsor(s):**LifeArc

**Program Title:** [Coronavirus therapeutics – call for rapid deployment](https://www.lifearc.org/funding/covid-19/covid-19-funding)

**Deadline:** April 6, 2021

**Description of Opportunity:** LifeArc invites applications for its coronavirus therapeutics call. This supports the identification of therapeutics that can be rapidly deployed to treat COVID-19. The aim is to run trials in patients during the current epidemic. The primary purpose is to accelerate availability of treatments for patients and it is therefore expected that applicants will already have material available for testing and a plan for rapid scale up of clinical material. Priority will be given to projects that have a clear path and availability for patients in a 6-12 month timeframe.

**32) Sponsor(s):**National Institutes of Health (NIH)

**Program Title:** [Supplements For Research on Biological Effects of the 2019 Novel Coronavirus on the Nervous System](https://grants.nih.gov/grants/guide/notice-files/NOT-NS-20-051.html)

**Deadline:** April 14, 2021

**Description of Opportunity:** NINDS is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on Coronavirus Disease 2019 (COVID-19) and on biological effects on the nervous system of its causative agent, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Research of interest must fall within NINDS’s scientific mission, which is to support basic, translational, and clinical neuroscience research to expand fundamental knowledge about the brain and nervous system and to use that knowledge to reduce the burden of neurological disease.

Research Objectives:

In order to rapidly improve our understanding of the neurological consequences of infection of SARS-CoV-2 and of COVID-19, NINDS is encouraging the submission of applications for supplements to address the biology, pathophysiology, prevention, diagnosis, sequelae, or treatment of the 2019 Novel Coronovirus that are directly related to the NINDS mission.

**33) Sponsor(s):**National Institutes of Health (NIH)

**Program Title:** [Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements and Urgent Competitive Revisions for Mental Health Research on the 2019 Novel Coronavirus](https://grants.nih.gov/grants/guide/notice-files/NOT-MH-20-047.html)

**Deadline:** April 15, 2021

**Description of Opportunity:** NIMH is issuing this Notice of Special Interest (NOSI) to highlight interest in research to strengthen the mental health response to Coronavirus Disease 2019 (COVID-19) caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and to future public health emergencies, including pandemics. NIMH is especially interested in research to provide an evidence base for how a disrupted workforce may adequately respond/adapt to and maintain services or provide additional care for new or increasing mental health needs, as well as to learn about the effects of the virus and public health measures to prevent spread of COVID-19 that may have an impact on mental health. Research addressing the intersection of COVID-19, mental health, and HIV treatment and prevention are also of interest to NIMH.

**34) Sponsor(s):**National Institutes of Health (NIH)

**Program Title:** [Notice of Special Interest: Availability of Administrative Supplements and Competitive Revision Supplements on Coronavirus Disease 2019 (COVID-19) within the Mission of NIAAA](https://grants.nih.gov/grants/guide/notice-files/NOT-AA-20-011.html)

**Deadline:** April 15, 2021

**Description of Opportunity:** The impact of the COVID-19 pandemic on the nation is vast, especially on health and well-being. Research suggests that alcohol consumption tends to increase during times of duress and uncertainty such as disasters and other traumatic events, and as such alcohol is often misused to cope with stress, anxiety, and other uncomfortable emotions. In addition, the misuse of alcohol to cope with the stress as a result of physical distancing and other policy measures, and a lack of access to supportive social networks and treatment for people with pre-existing alcohol use disorder (AUD) are significant concerns during the pandemic. These outcomes are particularly challenging with respect to COVID-19 because alcohol misuse can interfere with normal immune system function and elevate susceptibility to viral infections of the respiratory system. Alcohol-associated damage to the liver, heart, and other organs may also complicate health outcomes in individuals with COVID-19. These myriad physical and behavioral health outcomes related to alcohol and COVID-19 present a range of urgent research needs and opportunities.

Research is needed to understand the potentially complex relationships between alcohol consumption and COVID-19 related-outcomes to enhance the nation’s response to the current pandemic. The outcomes include overt pathophysiology and the impact of social and policy measures on COVID-19 outcomes. Such studies also will help to lay the groundwork for responding to future public health emergencies. This NOSI encourages applications, in the form of urgent competitive revisions and administrative supplements to existing grants and cooperative agreements, to assess the impact of alcohol as a biological contributor to COVID-19 outcomes, to assess behavioral, social, and economic consequences of the pandemic and to assess the responses that the pandemic has provoked as they relate to alcohol consumption and related outcomes.

NIAAA is encouraging research in the following areas, including those that capitalize on existing research cohorts, to investigate urgent research questions of significance to the COVID-19 pandemic within the general population and among underserved populations, such as racial, ethnic and gender minorities, individuals with low socioeconomic status, and those who are incarcerated or homeless.

**35) Sponsor(s):**National Institutes of Health (NIH)

**Program Title:** [Notice of Special Interest (NOSI): NIA Availability of Administrative Supplements and Revision Supplements on Coronavirus Disease 2019 (COVID-19)](https://grants.nih.gov/grants/guide/notice-files/NOT-AG-20-022.html)

**Deadline:** May 1, 2021

**Description of Opportunity:** NIA is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on Coronavirus Disease 2019 (COVID-19). The mission of NIA is to support and conduct genetic, biological, clinical, behavioral, social, and economic research on aging. This NOSI supports mission critical areas of research for NIA as they relate to the COVID-19 pandemic. In order to rapidly improve our understanding and available control measures for 2019-nCoV, NIA is encouraging the submission of applications for either Administrative Supplements ([PA-18-591](https://grants.nih.gov/grants/guide/pa-files/PA-18-591.html)) or Competitive Revisions ([PA-18-935](https://grants.nih.gov/grants/guide/pa-files/pa-18-935.html)) to active grants.

**36) Sponsor(s):**National Institutes of Health (NIH)

**Program Title:** [Notice of Special Interest (NOSI): Competitive and Administrative Supplements for the Impact of COVID-19 Outbreak on Minority Health and Health Disparities](https://grants.nih.gov/grants/guide/notice-files/NOT-MD-20-019.html)

**Deadline:** May 1, 2021

**Description of Opportunity:** The National Institute on Minority Health and Health Disparities (NIMHD) is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on the impact of the novel Coronavirus (SARS-CoV-2) pandemic causing COVID-19 disease outbreaks and the resulting disruptions on individual and social wellbeing, health services use, and health outcomes for NIH-designated health disparity populations.

**37) Sponsor(s):**Centers for Disease Control and Prevention

**Program Title:** [Coronavirus Response Fellowship](https://www.zintellect.com/Opportunity/Details/CDC-CSTLTS-2020-0086)

**Deadline:** May 1, 2021

**Description of Opportunity:** A research opportunity is currently available with the Center for State, Tribal, Local, and Territorial Support (CSTLTS) at the Centers for Disease Control and Prevention (CDC) in Atlanta, Georgia. CSTLTS seeks to foster deeper engagement between CDC senior leaders and public health leadership from the U.S. territories and freely- associated states.

**38) Sponsor(s):**National Institutes of Health (NIH)

**Program Title:** [Notice of Special Interest (NOSI): NIEHS Support for Understanding the Impact of Environmental Exposures on Coronavirus Disease 2019 (COVID-19)](https://grants.nih.gov/grants/guide/notice-files/NOT-ES-20-015.html)

**Deadline:** May 3, 2021

**Description of Opportunity:** NIEHS is issuing this Notice of Special Interest (NOSI) to address the urgent need for mission-relevant research to understand the impact of environmental exposures on Coronavirus Disease 2019 (COVID-19) and its causative agent, the severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2). NIEHS is particularly interested in applications that will provide insight into the role of environmental exposures in pathogenicity, transmission, individual susceptibility, or prevention and intervention strategies.

**39) Sponsor(s):**Department of State – Office of the Secretary

**Program Title:** [COVID-19 Private Sector Engagement & Partnership Fund](https://www.grants.gov/web/grants/view-opportunity.html?oppId=328509)

**Deadline:** May 28, 2021

**Description of Opportunity:** The U.S. Department of State, Office of Global Partnerships (E/GP) is pleased to announce the COVID-19 Private Sector Engagement & Partnership Fund (Fund) Annual Program Statement (APS) that will be used make assistance awards.. This APS is being done in partnership the U.S. Agency for International Development and concept papers may be transferred to the Agency based upon a determination of suitability for award and administration. USAID’s policies and procedures will apply to concept papers that are transferred to the Agency. This APS utilizes a two-step process. Applicants must first submit a concise (5-page) concept paper designed to clearly communicate their program idea and objectives. This is not a full proposal. The purpose of the concept paper is to allow applicants to submit program ideas for evaluation prior to requiring the development of a full proposal application. After merit review of eligible concept papers, selected applicants will be invited to expand on their program idea(s) by submitting a full proposal application. Full proposals will go through a second merit review before a final funding decision is made. E/GP has outlined the process through which potential applicants may apply in Appendix 1 to this APS.

**40) Sponsor(s):**National Institutes of Health (NIH)

**Program Title:** [Notice of Special Interest (NOSI) regarding the Availability of Emergency Competitive Revisions for Select Research Activities related to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19)](https://grants.nih.gov/grants/guide/notice-files/NOT-AI-20-059.html)

**Deadline:** Applications will be accepted on a rolling basis July 2, 2020 to July 2, 2021 through 5:00 PM local time of the applicant organization

**Description of Opportunity:** NIAID is issuing this Notice of Special Interest (NOSI) to highlight very specific and limited needs for Competitive Revision applications to active NIAID grants in order to further build the infrastructure that NIAID needs to support the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) research response. This NOSI replaces [NOT-AI-20-034](https://grants.nih.gov/grants/guide/notice-files/NOT-AI-20-034.html) which was rescinded with this issuance of this Notice.

**41) Sponsor(s):**National Institutes of Health (NIH)

**Program Title:** [Limited Competition Emergency Awards: Shared Personal Protective Equipment Resources for COVID-19 Related Vaccine and Treatment Clinical Trials and Clinical Studies (S10 Clinical Trial Not Allowed)](https://grants.nih.gov/grants/guide/pa-files/PAR-20-256.html)

**Deadline:** July 7, 2021

**Description of Opportunity:** The purpose of this public health emergency funding opportunity is to provide Personal Protective Equipment (PPE) to directly support the needs of the NIAIDs vaccine and treatment clinical trials and clinical studies for COVID-19. This program will ensure that adequate protective equipment is available to directly assist in safely carrying out the clinical activities and direct interactions with the patients participating in the trial. Eligibility is limited to recipients conducting COVID-related clinical research and clinical studies supported by NIAIDs emergency appropriation provided by The Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 and The Coronavirus Aid, Relief and Economic Security (CARES) Act.

**42) Sponsor(s):**National Institutes of Health (NIH)

**Program Title:** [Limited Competition Emergency Awards: Shared Personal Protective Equipment Resources for COVID-19 Related Vaccine and Treatment Clinical Trials and Clinical Studies (S10 Clinical Trial Not Allowed)](https://grants.nih.gov/grants/guide/pa-files/PAR-20-256.html#_Section_III._Eligibility)

**Deadline:** Applications for this limited competition FOA will be accepted on a rolling basis, beginning July 13, 2020 until July 08, 2021

**Description of Opportunity:** The purpose of this public health emergency funding opportunity is to provide Personal Protective Equipment (PPE) to directly support the needs of the NIAID’s vaccine and treatment clinical trials and clinical studies for COVID-19. This program will ensure that adequate protective equipment is available to directly assist in safely carrying out the clinical activities and direct interactions with the patients participating in the trial. Eligibility is limited to recipients conducting COVID-related clinical research and clinical studies supported by NIAID’s emergency appropriation provided by “The Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020” and “The Coronavirus Aid, Relief and Economic Security (CARES) Act”.

**43) Sponsor(s):**National Institutes of Health (NIH)

**Program Title:** [Notice of Special Interest: Clinical and Translational Science Award (CTSA) Program Applications to Address 2019 Novel Coronavirus (COVID-19) Public Health Need](https://grants.nih.gov/grants/guide/notice-files/NOT-TR-20-011.html)

**Deadline:** July 9, 2021

**Description of Opportunity:** National Center for Advancing Translational Sciences (NCATS) is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on the 2019 novel Coronavirus (COVID-19). NCATS is particularly interested in projects focusing on the use of informatics solutions to diagnose cases and the use of CTSA-supported core resources (e.g., advanced scientific instruments, highly-specialized facilities, and regulatory expertise) to facilitate research on COVID-19 and advance the translation of research findings into diagnostics, therapeutics, and vaccines.

**44) Sponsor(s):**National Institutes of Health (NIH)

**Program Title:** [Notice of Special Interest (NOSI): Select Research Areas for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19)](https://grants.nih.gov/grants/guide/notice-files/NOT-AI-20-051.html)

**Deadline:** September 7, 2021

**Description of Opportunity:** NIAID is issuing this Notice of Special Interest (NOSI) to highlight the need for research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) in select scientific areas.

**45) Sponsor(s):**National Institutes of Health (NIH)

**Program Title:** [Notice of Special Interest (NOSI): Availability of Emergency Awards for Limited Clinical Trials to Evaluate Therapeutic and Vaccine Candidates Against SARS-CoV-2](https://grants.nih.gov/grants/guide/notice-files/NOT-AI-20-065.html)

**Deadline:** September 14, 2021

**Description of Opportunity:** This Notice of Special Interest encourages cooperative agreement applications for implementation of investigator-initiated high-risk clinical trials, as defined by NIAID in [PAR-18-633](https://grants.nih.gov/grants/guide/pa-files/par-18-633.html) and [NOT-AI-16-084](https://grants.nih.gov/grants/guide/notice-files/NOT-AI-16-084.html), that will augment ongoing and planned clinical trials of therapeutic and vaccine candidates directed against SARS-CoV-2 to evaluate:

* SARS-CoV-2 candidate vaccines
* non-vaccine biomedical prevention of SARS-CoV-2 infection and/or COVID-19
* therapeutic approaches to treat COVID-19

Please note, studies evaluating behavioral interventions (e.g., impact of face masks, hand- washing, social distancing) and those focused on disinfecting surfaces and equipment are not responsive and will not be considered for this NOSI initiative.

**46) Sponsor(s):**National Institutes of Health (NIH)

**Program Title:** [Notice of Special Interest (NOSI) regarding the Availability of Emergency Competitive Revisions to Existing NIH Grants and Cooperative Agreements for Tissue Chips Research on the 2019 Novel Coronavirus](https://grants.nih.gov/grants/guide/notice-files/NOT-TR-20-017.html)

**Deadline:** January 25, 2022

**Description of Opportunity:** NCATS is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on the COVID-19. NCATS is especially interested in research in the use of microphysiological systems or tissue chips in collecting and examining data on the risks and outcomes for COVID-19 infection, and advance the translation of research findings into diagnostics, therapeutics, and vaccines.

**47) Sponsor(s):**National Institutes of Health (NIH)

**Program Title:** [Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements for Tissue Chips Research on the 2019 Novel Coronavirus](https://grants.nih.gov/grants/guide/notice-files/NOT-TR-20-016.html)

**Deadline:** January 25, 2022

**Description of Opportunity:** NCATS is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on the COVID-19. NCATS is especially interested in research in the use of microphysiological systems or tissue chips in collecting and examining data on the risks and outcomes for COVID-19 infection, and advance the translation of research findings into diagnostics, therapeutics, and vaccines.

**48) Sponsor(s):**Department of Defense

**Program Title:** [U.S. Army Contracting Command Medical Countermeasures (MCM) Commercial Solutions Opening (CSO)](https://beta.sam.gov/opp/07c28cf32d6244bc877fbf6dd1e2d2bc/view)

**Deadline:** September 30, 2022

**Description of Opportunity:** This is a Program Announcement for a Medical Countermeasures (MCM) Commercial Solutions Opening (CSO) W911QY-20-S-C001 by the U.S. Army Contracting Command – Aberdeen Proving Ground, Natick Division (ACC-APG-Natick) on behalf of Joint Program Executive Office - Chemical Biological Radiological Nuclear Defense (JPEO-CBRND) and Biomedical Advanced Research and Development Authority (BARDA). This CSO is in support of Operation Warp Speed in response to the Corona Virus 2019 (COVID-19) pandemic. This CSO Solicitation is a competitive solicitation that is continuously open until September 30, 2022. The government reserves the right to extend this CSO beyond the open until date by amendment if the authority is extended. See attachment ACC-APG-Natick MCM CSO Solicitation W911QY-20-S-C001 for the MCM solicitation. The first AoI is posted with the release of the MCM CSO Solicitation. Future AoI’s will be posted as a Related Notice to this Solicitation.

**49) Sponsor(s):**Department of Health and Human Services

**Program Title:** [BARDA's Division of Research, Innovation & Ventures (DRIVe) Easy Broad Agency Announcement](https://beta.sam.gov/opp/f922eb52cec446c5875811752bf2d34c/view) (revised)

**Deadline:** February 3, 2023

**Description of Opportunity:** Please see Special Instructions 010 Issuance for Easy Broad Agency Announcement (EZ-BAA) BAA-20-100-SOL-0002. Under these Special Instructions 010, BARDA is adding topic #4.1-E under its temporary AOI #4: COVID-19 as part of its EZ-BAA (BAA-20-100-SOL-0002).

The development of adjunctive diagnostic technologies with near-term impact that are critical to improving the efficiency and effectiveness of our health infrastructure during the COVID-19 outbreak. These technologies may empower the patient through providing a means of self-monitoring or empower the healthcare provider through remote monitoring or evaluation and diagnostic capability throughout the care continuum of the patient (i.e. pre-hospital, inpatient, and post-discharge).

There is also a need to rapidly assess and diagnose severity of illness in order to triage patients for care or to aid in early recognition of decompensation for improved clinical management of patient.

These technologies may include, but are not limited to, smartphone mobile applications, wearables, or non (or minimally) invasive sensors that can measure/monitor host-signature or diagnose response to infection, telehealth applications, EHR based tools, algorithms that can predict, identify or prognosticate risk trajectories, clinical decision support software, or continuous monitoring

devices.

These technologies should be in advanced development and ready for clinical validation. These technologies should be capable of capturing and quantifying a broad range of host biological, immunological, biometric, clinical, laboratory, and/or physiological data. In addition, technologies that incorporate novel informatics approaches to data collection, reporting, and analysis are of interest. Pathogentargeted and serology diagnostics, as well as bench-top diagnostics, are not of

interest for this topic at this time.

To be considered relevant under this topic, respondents should have a need to assess clinical validation through conducting a pilot study that meets the following requirements:

1) Total period of performance should have impact for this current COVID-19 outbreak. After clinical validation, technology should have the ability to be rapidly scaled and deployed under an accelerated timeline of less than 90 days.

2) Software tools should be able to be integrated into EHRs or deployed in less than 30 days.

3) Significant preliminary COVID-19 data to support utility of technology for COVID-19.

4) Requires minimal infrastructure or training to deploy and support.

5) Achieved FDA regulatory clearance/approval or have identified a clear regulatory path for deployment, if applicable to technology.

6) Demonstrates a clear commercialization strategy to expand use.

Priority will be given to products manufactured in the United States.

AOI #4.1-E: Pediatric Diagnostic Tools for Severe COVID-19 Disease and MIS-C The clinical presentation of COVID-19 in children is not fully understood and remains challenging to address. Many children infected with SARS-CoV-2 are asymptomatic or display mild symptoms, but the risk of severe COVID-19 disease that may lead to hospitalization and in some cases, sepsis, still exists. More recently, Multisystem Inflammatory Syndrome in Children (MIS-C) has been described as a condition where inflammation affects multiple organs causing a range of symptoms that may occur weeks after infection with, or exposure to, SARSCoV-2. There is a need to develop solutions that recognize or predict severe COVID19 disease in children and/or subsequent complications like MIS-C which may arise outside of apparent symptomatic infection.

Diagnostic technologies that can specifically identify and distinguish severe COVID19 disease from mild illness in children and/or predict the onset of MIS-C are needed to aid in clinical management of these patients. These host-based or clinical technologies may include, but are not limited to:

1) In vitro diagnostics, EHR based tools, or algorithms that can collate data to predict, identify or prognosticate risk trajectories.

2) Clinical decision support software, or remote/continuous monitoring devices appropriately sized for children.

Technologies should be capable of capturing and quantifying a broad range of host biological, immunological, clinical, laboratory, and/or physiological data as appropriate to predict and identify severe pediatric COVID-19 and/or MIS-C. Pathogen-based approaches are not of interest at this time nor technologies that cannot distinguish these severe conditions from asymptomatic or mild COVID-19.

To be considered relevant under this topic, technologies should meet the following minimum requirements:

1) Completed initial studies with pediatric COVID-19 samples with sufficient performance metrics of the technology to identify severe outcomes.

2) Seeking FDA regulatory clearance/approval or EUA if applicable.

3) Have identified clinical study site partners, if needed, for larger scale or prospective studies.

4) Specifically focused on pediatric indication.

5) Focused on product development, not surveillance or epidemiological research.

6) After seeking regulatory approvals, have ability to deploy in multiple US locations within the next 6-12 months in order to have impact during this COVID-19 pandemic.

Priority will be given to products manufactured in the United States. **See link for revisions**

**50) Sponsor(s):**Department of Health and Human Services

**Program Title:** [SARS-CoV-2 (COVID-19) Program Activities](https://www.grants.gov/web/grants/view-opportunity.html?oppId=328065)

**Deadline:** Forecast

**Description of Opportunity:**The Office of the Assistant Secretary for Health (OASH) has established the Laboratory and Diagnostics Working Group (LDWG) seeking submissions to a Broad Agency Announcement (BAA) “to prevent, prepare for, and respond to coronavirus, domestically or internationally, for necessary expenses to research, develop, validate, manufacture, purchase, administer, and expand capacity for COVID–19 tests to effectively monitor and suppress COVID–19…” (Paycheck Protection Program and Healthcare Enhancement Act (P.L. 116-139)). OASH/LDWG seeks proposals for projects that will further enable the coordination and development of testing and associated products that meet the current and future needs, and the effective transition of technology into broad use without impediments. The primary areas of focus should specifically include (1) Scaling and Networking of Technologies, and (2) Testing Demonstrations & Technical Assistance. Specifically, OASH is interested in submissions that will substantially increase our testing capacity and quality in the near term, and do not fall within the scope of other HHS programs.

When posted, the funding opportunity announcement (FOA) will provide guidance for applicants on the submission of short white papers, which after review, may be followed by full proposal submissions for consideration for funding. Applicants will have the option of forgoing the white paper submission for direct submission of a full proposals. Applications will be accepted and reviewed on a rolling basis to address immediate public needs. Applicants must submit white papers and applications through Grants.gov according to the instructions in the FOA. Applicants must have an active SAM registration at the time of submission and maintain an active registration throughout the review process and during any award that may result.

**51) Sponsor(s):**Department of Health and Human Services – Agency for Health Care Research and Quality

**Program Title:** [Notice of Intent: Revision Supplements to Existing AHRQ Grants and Cooperative Agreements to Address Health System Responsiveness to COVID-19](https://grants.nih.gov/grants/guide/notice-files/NOT-HS-20-007.html)

**Deadline:** Notice of Intent

**Description of Opportunity:**AHRQ intends to publish a new funding notice allowing requests for urgent revision supplements to existing AHRQ grants and cooperative agreements to address health system responsiveness to COVID-19. AHRQ intends to allow grantees with active AHRQ research grants to submit requests for competitive revision supplements to address timely health system and healthcare professional response to COVID-19. Grant activity codes to be included or excluded from the funding notice will specified in the announcement.

It is expected that competitive revision supplement requests will capitalize on the expertise of grant personnel and the institutional environment to expand the specific aims of the on-going research to develop high-impact new knowledge concerning COVID-19. Competitive revision supplements will be limited in duration (perhaps 12 months). The amount of supplemental funds that may be requested will be limited, and will be specified in the funding notice. AHRQ expects to make at least $2.5M available to fund meritorious revision supplements in FY2020. AHRQ plans to release the supplement announcement in April 2020 with an opening date in mid-May.

Please also see AHRQ’s Notice of Intent to publish a new FOA requesting new competitive applications targeting the evaluation of health system responsiveness to COVID-19.

**52) Sponsor(s):**National Institutes of Health (NIH)

**Program Title:** [Notice of Special Interest (NOSI) regarding the Availability of Emergency Competitive Revisions for Research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease](https://grants.nih.gov/grants/guide/notice-files/NOT-AI-20-031.html)

**Deadline:** Varies

**Description of Opportunity:** NIAID is issuing this Notice of Special Interest (NOSI) to highlight the need for research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19). NIAID is particularly interested in projects focusing on viral natural history, pathogenicity, transmission, as well as projects developing medical countermeasures and suitable animal models for pre-clinical testing of vaccines and therapeutics against SARS-CoV-2/COVID-19.

**53) Sponsor(s):**National Institutes of Health (NIH)

**Program Title:** [Notice of Special Interest (NOSI): NIEHS Support for Understanding the Impact of Environmental Exposures on Coronavirus Disease 2019 (COVID-19)](https://grants.nih.gov/grants/guide/notice-files/NOT-ES-20-020.html)

**Deadline:** Varies

**Description of Opportunity:** NIEHS is issuing this Notice of Special Interest (NOSI) to address the urgent need for mission-relevant research to understand the impact of environmental exposures on Coronavirus Disease 2019 (COVID-19) and its causative agent, the severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2). NIEHS is particularly interested in applications that will provide insight into the role of environmental exposures in pathogenicity, transmission, individual susceptibility, or prevention and intervention strategies.

**54) Sponsor(s):**National Institutes of Health (NIH)

**Program Title:** [Competing Revisions to Existing NIH Grants and Cooperative Agreements (Clinical Trial Optional)](https://grants.nih.gov/grants/guide/pa-files/PA-20-163.html)

**Deadline:** Varies

**Description of Opportunity:**The National Institutes of Health (NIH) hereby notifies NIH award recipients that funds may be available for revision applications to support the expansion of existing projects and/or programs within the awarding IC identified in the competitive revision NOSI. Applications for Revisions will be evaluated for scientific and technical merit by (an) appropriate Scientific Review Group(s), in accordance with NIH peer review policy and procedures, using the stated review criteria.

Only applications submitted in response to a NOSI published by an NIH Institute or Center will be allowed to apply to this FOA.

**55) Sponsor(s):**National Institutes of Health (NIH)

**Program Title:** [Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement - Clinical Trial Optional)](https://grants.nih.gov/grants/guide/pa-files/PA-20-135.html)

**Deadline:** Varies

**Description of Opportunity:**The National Institutes of Health (NIH) hereby notify the applicant community that funds may be available for applications based on a presidentially declared disaster under the Stafford Act, a public health emergency declared by the Secretary, HHS, or other local, regional or national disaster. Applications in response to Emergency Notices of Special Interest (NOSIs) will be routed directly to the NIH awarding component signed on to the Emergency NOSI.

**56) Sponsor(s):**National Institutes of Health (NIH)

**Program Title:** [Notice of NHGRI’s Participation in PA-18-935 "Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement - Clinical Trial Optional)"](https://grants.nih.gov/grants/guide/pa-files/pa-18-935.html)

**Deadline:** Varies

**Description of Opportunity:**The purpose of this Notice is to inform applicants that the National Human Genome Research Institute (NHGRI) will participate, effective immediately, in **PA-18-935** "Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement - Clinical Trial Optional)".

**57) Sponsor(s):**National Science Foundation (NSF)

**Program Title:** [Dear Colleague Letter: Provisioning Advanced Cyberinfrastructure to Further Research on the Coronavirus Disease 2019 (COVID-19)](https://www.nsf.gov/pubs/2020/nsf20055/nsf20055.jsp)

**Deadline:** No firm deadline announced

**Description of Opportunity:** Through this Dear Colleague Letter, the Office of Advanced Cyberinfrastructure (OAC) within the Directorate for Computer and Information Science and Engineering is inviting RAPID proposals and supplemental funding requests to existing awards that address COVID-19 challenges through data and/or software infrastructure development activities. Such activities would be funded by the [Computational and Data-Enabled Science and Engineering (CDS&E) program](https://www.nsf.gov/funding/pgm_summ.jsp?pims_id=504813) or the [Cyberinfrastructure for Sustained Scientific Innovation (CSSI) program](https://www.nsf.gov/funding/pgm_summ.jsp?pims_id=505505).RAPID is a type of proposal used when there is a severe urgency with regard to availability of, or access to, data, facilities or specialized equipment, including quick-response research on natural or anthropogenic disasters and similar unanticipated events. PI(s) must contact the NSF Program Officer(s) whose expertise is most germane to the proposal topic before submitting a RAPID proposal. This will facilitate determining whether the proposed work is appropriate for RAPID funding.

**58) Sponsor(s):**National Science Foundation (NSF)

**Program Title:** [Dear Colleague Letter on the Coronavirus Disease 2019 (COVID-19)](https://www.nsf.gov/pubs/2020/nsf20052/nsf20052.jsp)

**Deadline:** No firm deadline announced

**Description of Opportunity:** In light of the emergence and spread of the coronavirus disease 2019 (COVID-19) in the United States and abroad, the National Science Foundation (NSF) is accepting proposals to conduct non-medical, non-clinical-care research that can be used immediately to explore how to model and understand the spread of COVID-19, to inform and educate about the science of virus transmission and prevention, and to encourage the development of processes and actions to address this global challenge.

**59) Sponsor(s):**National Institutes of Health (NIH)

**Program Title:** [Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement -  Clinical Trial Optional)](https://grants.nih.gov/grants/guide/pa-files/PA-18-935.html)

**Deadline:** Varies

**Description of Opportunity:** The National Institutes of Health (NIH) hereby notify Principal Investigators holding specific types of NIH research grants, listed in the full Funding Opportunity Announcement (FOA) that funds may be available for competitive revisions to meet immediate needs to help address a specific public health crisis in a timely manner, but that were unforeseen when the new or renewal application or grant progress report for non-competing continuation support was submitted. Applications for Urgent Competitive Revisions will be routed directly to the NIH awarding component listed on the NoA of the most recent parent award. Only applications submitted in response to an Urgent Guide Notice published by an IC will be allowed to apply to this FOA.

**60) Sponsor(s):**National Institute of Health Research (NIHR)

**Program Title:** [Travel and Subsistence Funding to Support LMIC Engagement During the COVID-19 Outbreak](https://www.nihr.ac.uk/documents/travel-and-subsistence-funding-to-support-lmic-engagement-during-the-covid-19-outbreak-guidance/24356)

**Deadline:** Open until further notice

**Description of Opportunity:** This scheme provides travel and subsistence funding to support delivery of technical expertise in the global response to Covid-19. This service is not delivered to, or on behalf of, the Department of Health and Social Care (DHSC)/the National Institute for Health Research (NIHR) and does not constitute a contractual or service agreement, employer/employee or agent/principal relationship between any institution, body or person and the DHSC/NIHR.

**61) Sponsor(s):**National Institutes of Health (NIH)

**Program Title:** [Fast-Track Program for COVID-19 Test Development and Distribution Innovative Technologies to Increase U.S. Capacity for COVID-19 Testing](https://www.poctrn.org/radx)

**Deadline:** Accepting proposals for support on a rolling basis until further notice

**Description of Opportunity:** As part of this initiative, NIH is urging all scientists and inventors with a rapid testing technology to compete in a national COVID-19 testing challenge for a share of up to $500 million over all phases of development. The technologies will be put through a highly competitive, rapid three-phase selection process to identify the best candidates for at-home or point-of-care tests for COVID-19. Finalists will be matched with technical, business and manufacturing experts to increase the odds of success. If certain selected technologies are already relatively far along in development, they can be put on a separate track and be immediately advanced to the appropriate step in the commercialization process. The goal is to make millions of accurate and easy-to-use tests per week available to all Americans by the end of summer 2020, and even more in time for the flu season.

**62) Sponsor(s):**California Institute for Regenerative Medicine (CIRM)

**Program Title:** [Special Call for COVID-19 Projects](https://www.cirm.ca.gov/sites/default/files/files/funding_page/COVID19-SA_0.pdf)

**Deadline:** Rolling

**Description of Opportunity:** The mission of California Institute for Regenerative Medicine (CIRM) is to accelerate stem cell treatments to patients with unmet medical needs. Given the growing surge of COVID-19 cases in California and throughout the world, CIRM is issuing this special announcement to support promising discovery, preclinical and clinical trial stage projects that could quickly advance treatments to COVID-19 patients in need. CIRM is utilizing its established partnering opportunities across Discovery (DISC2), Translational (TRAN1), and Clinical (CLIN1, CLIN2) stages to provide support for COVID-19 related projects.

**63) Sponsor(s):**Alianza UCMX

**Program Title:** [Alianza UCMX Supplemental COVID-19 Funding Opportunity](https://ucmexus.ucr.edu/funding/alianza-pdf/Supplemental_Funding_Opportunity_final.pdf)

**Deadline:** Rolling

**Description of Opportunity:** Alianza UCMX (alianzaucmx.ucr.edu) is proud to release the UC MEXUS (ucmexus.ucr.edu) supplemental funding opportunity for UC faculty undertaking research on COVID-19 who want to engage with Mexico. To be eligible, UC faculty must be a recipient of a coronavirus-related project award and be interested in expanding their academic engagement with faculty; graduate, professional, and undergraduate students; or researchers from a Mexican higher education institution.

**64) Sponsor(s):**Department of Commerce

**Program Title:** [FY 2020 EDA Public Works and Economic Adjustment Assistance Programs including CARES Act Funding](https://www.grants.gov/web/grants/view-opportunity.html?oppId=321695)

**Deadline:** Rolling

**Description of Opportunity:** Under this NOFO, EDA solicits applications from applicants in rural and urban areas to provide investments that support construction, non-construction, technical assistance, and revolving loan fund projects under EDA’s Public Works and EAA programs. Grants and cooperative agreements made under these programs are designed to leverage existing regional assets and support the implementation of economic development strategies that advance new ideas and creative approaches to advance economic prosperity in distressed communities. EDA provides strategic investments on a competitive- merit-basis to support economic development, foster job creation, and attract private investment in economically distressed areas of the United States. If you are interested in applying for a project of national impact/scope under the CARES Act; please inquire at [RNTA@eda.gov](mailto:RNTA@eda.gov).

**65) Sponsor(s):**National Institutes of Health (NIH)

**Program Title:** [Urgent Phase I/II Clinical Trials to Repurpose Existing Therapeutic Agents to Treat COVID-19 Sequelae (U01 Clinical Trial Required)](https://grants.nih.gov/grants/guide/rfa-files/RFA-TR-20-003.html)

**Deadline:** Rolling

**Description of Opportunity:** The purpose of this urgent funding opportunity announcement is to invite applications to repurpose existing therapeutic agents to treat Coronavirus Disease 2019 (COVID-19) sequelae and associated complications that result from Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infections. The therapeutic agent must have already completed at least a Phase I clinical trial for a different indication, and not require additional regulatory studies for the new indication prior to starting a clinical trial.

**66) Sponsor(s):**The Gates Foundation, Wellcome Trust, and the Mastercard Impact Fund

**Program Title:** [The COVID-19 Therapeutics Accelerator](https://wellcome.ac.uk/news/wellcome-pledges-50-million-new-initiative-speed-development-covid-19-treatments)

**Deadline:** Varies

**Description of Opportunity:** Currently there are no approved treatments for COVID-19. This new initiative aims to fill that gap by accelerating and evaluating new and repurposed drugs and biologics to treat patients with COVID-19 in the immediate term, and other viral pathogens in the longer-term. The partners are committed to equal access, ensuring treatments are accessible and affordable in low-resource settings.

**67) Sponsor(s):**Mozilla

**Program Title:** [COVID-19 Solutions Fund](https://blog.mozilla.org/blog/2020/03/31/moss-launches-covid-19-solutions-fund/)

**Deadline:** Continuous

**Description of Opportunity:** As part of the COVID-19 Solutions Fund, we will accept applications that are hardware (e.g., an open source ventilator), software (e.g., a platform that connects hospitals with people who have 3D printers who can print parts for that open source ventilator), as well as software that solves for secondary effects of COVID-19 (e.g., a browser plugin that combats COVID related misinformation).

**68) Sponsor(s):**George Mason University; Mercatus Center; Emergent Ventures

**Program Title:** [Fast Funding for COVID-19 Science](https://fastgrants.org/)

**Deadline:** Continuous

**Description of Opportunity:** Science funding mechanisms are too slow in normal times and may be much too slow during the COVID-19 pandemic. Fast Grants are an effort to correct this.  
  
If you are a scientist at an academic institution currently working on a COVID-19 related project and in need of funding, we invite you to apply for a Fast Grant.

**69) Sponsor(s):**Adira Foundation

**Program Title:** [Fast-Track Grant Response: COVID-19](https://adirafoundation.org/programs/adiras-fast-track-grant-response-covid-19/)

**Deadline:** Continuous

**Description of Opportunity:** Adira Foundation is redirecting some funding to meet immediate and pressing needs. Adira is fast tracking the grant application process so that organizations seeking financial support can act quickly to provide emergency response, direct-service programs to the Alzheimer's disease, ALS, Huntington's disease, multiple sclerosis, or Parkinson's disease communities.

**70) Sponsor(s):**Open Road Alliance

**Program Title:** [Direct COVID-19 Response – Charitable Grant](https://openroadalliance.org/covid-19/)

**Deadline:** Continuous

**Description of Opportunity:** The effect of the COVID-19 pandemic on the impact sector has reached natural disaster proportions in its scope and scale, which means that the global need for our 'emergency' capital vastly outstrips our available resources. Charitable Grants will only be offered to organizations responding directly to COVID-19. This grant is for organizations engaging in direct COVID-19 response. We will prioritize organizations and activities that have a clear and direct role in `flattening the curve' and thus limiting, shortening, or minimizing the economic and social, as well as health effects of the pandemic. Slowing and stopping the spread of COVID-19 is directly linked to reducing and limiting the economic and social hardship our communities are experiencing.

**71) Sponsor(s):** United States Agency for International Development (USAID)

**Program Title:** [COVID-10 Funding Requests and Unsolicited Proposals](https://www.usaid.gov/coronavirus/funding-requests-unsolicited-proposals)

**Deadline:** No firm deadline announced

**Description of Opportunity:** USAID is responding to the COVID-19 pandemic with decisive action at home and abroad. The priorities in the COVID-19 response are to protect the safety and health security of the global workforce, ensure that USAID can continue its life-saving mission across the world, and support partner countries in their response to COVID-19. Partners may submit unsolicited proposals to [COVID19\_Concepts@usaid.gov](mailto:COVID19_Concepts@usaid.gov).

**72) Sponsor(s):** State of California

**Program Title:** [State of California COVID-19 Technology Solutions](https://tech.covid19.ca.gov/)

**Deadline:** No firm deadline announced

**Description of Opportunity:** The State of California is interested in learning more about potential case management/CRM software solutions for COVID-19 contact tracing. Solutions should be scalable, proven, easy to learn and use, and HIPAA-compliant, with strong role management, the ability to easily configure COVID-19-specific scripts and alerts, the ability to easily support 3rd party integrations, and features (such as automated two-way messaging) that can help maximize the productivity of contact tracing staff.

The State is also interested in learning about potential solutions for contact tracing call center operations and management, including the ability to operate a HIPAA-compliant virtual call center with home-based agents, ramp up new staff quickly, and provide them with the support necessary to be successful.

**73) Sponsor(s):** Congressional Hispanic Caucus Institute (CHCI)

**Program Title:** [COVID-19 Response Fund as Economic Relief to Latino Community](https://chci.org/covid-19-response-fund/)

**Deadline:** No firm deadline announced

**Description of Opportunity:** The Congressional Hispanic Caucus Institute (CHCI) announced the launch of a COVID-19 Response Fund to provide economic relief to Hispanics who are among the hardest hit and most vulnerable communities impacted by the deadly Coronavirus outbreak. They are currently developing a list of qualified 501(c)(3) nonprofit organizations who have good reputations (for example, on GuideStar), and who provide direct services and other COVID-19 related support and resources to those in need. CHCI will distribute dollars received through the COVID-19 Response Fund to those organizations. The list of organizations will be posted on their website, available to the public.

**74) Sponsor(s):** National Institutes of Health (NIH)

**Program Title:** [Notice of Information: Contributing to the Global COVID-19 Crisis Response by Allowing Some NCI-supported Projects to be Redirected to COVID-19-related Research During the Crisis](https://grants.nih.gov/grants/guide/notice-files/NOT-CA-20-054.html)

**Deadline:** No firm deadline announced

**Description of Opportunity:** The COVID-19 pandemic is a global health crisis that has engaged the attention of researchers who want to be able to contribute their expertise and resources toward a better understanding of the impacts of SARS-CoV-2 infection and COVID-19 disease on cancer patients’ disease progression, response to therapy, care delivery, or survivorship.

NCI anticipates that in infrequent cases, NCI-funded investigators will have novel insights and research proposals of immediate relevance to SARS-CoV-2 and COVID-19. In those cases, but only for the duration of the present crisis, NCI would consider requests from its funded grantees and cooperative agreement awardees to engage in limited COVID-19 related research using part of their existing NCI-funded resources under the following conditions:

* Any proposed COVID-19 projects would have to be novel, innovative, compelling, and scientifically meritorious. Projects should have cancer relevance and the potential for high impact.
* Proposed projects should not duplicate other efforts or be simple extensions or modifications of ongoing research.
* Proposed projects must be able to start immediately and be time limited, not to exceed 1 year.
* If the proposed research requires access to laboratories and facilities currently not available, the sponsoring institution must provide explicit concurrence that those facilities would be made available for the project.
* The investigator must have the resource capacity within the existing NCI grant to pursue the project.

**75) Sponsor(s):** Novaritis Foundation

**Program Title:** [Novaritis US COVID-19 Initiatives](https://www.novartis.us/news/novartis-us-covid-19-initiatives)

**Deadline:** No firm deadline announced

**Description of Opportunity:** In response to the COVID-19 pandemic, the Novartis US Foundation has established the US COVID-19 Community Response Fund to support local initiatives and communities in the US impacted by the outbreak. The fund will provide up to USD $5 million over a one-year period for immediate response and recovery efforts related to the pandemic. Programs must support one or more of the three stated objectives:

* Strengthening local and national healthcare infrastructure to meet increased demand and protect frontline health workers
* Establishing digital platforms for COVID-19 related data collection, remote delivery of healthcare and effective dissemination of important public health information
* Creating or enhancing new community health programs specific to the pandemic response

**76) Sponsor(s):** Draper Richards Kaplan Foundation

**Program Title:** [DRK COVID-19 Urgent Response Initiative (CURI)](https://drive.google.com/file/d/1Dcj2zuFKE72caEBYz5ADOLDWeci802cD/view)

**Deadline:** No firm deadline announced

**Description of Opportunity:** The Draper Richards Kaplan Foundation invites applications for funding under its COVID-19 urgent response initiative. This supports innovative solutions that address time-critical social problems caused by the COVID-19 pandemic. Solutions should be fully scalable, lead to lasting change and be deployable within 30 days.